AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01082393 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: topical pimecrolimus treatment
Description: 4 applications (day 1, day 3, day 6 and day 10)
Study NCT01082393 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: local mometasone furoate treatment
Description: 4 applications (day 1, day 3, day 6 and day 10)
Study NCT01082393 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: cold cream
Description: 4 applications (day 1, day 3, day 6 and day 10)
Study NCT04205656 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Leukocyte-Poor Platelet Rich Plasma (LP-PRP)
Description: Participants will have a knee injected with Platelet-Rich Plasma (PRP) obtained from a venous whole blood draw from the vein.
Study NCT00761917 — intervention group
Intervention type: DEVICE
Intervention: Tear Film Analyzer
Description: tear film images
Study NCT04823559 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ThinkCancer workshop
Description: The proposed intervention, the ThinkCancer! Workshop, is practice-based and consists of themed sessions for both clinical and non-clinical staff, the co-production of a Cancer Safety Netting Plan (CSNP) and the appointment of a Cancer Safety Netting Champion (CSNC). The workshop aims to raise awareness and increase knowledge around current cancer diagnosis guidance and will be delivered over half a day during GP protected time in the form of face-to-face educational sessions. Sessions will consist of a series of interactive activities exploring existing processes within practices and developing plans for change to implement each component.
Study NCT04493918 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Mesenchymal Stem cell + Nacl 0.9%
Description: Patient who undergo surgery, debridement, decompression and posterior stabilization injection with Nacl 0.9% 2 ml + MSC 30 million unit
Study NCT04493918 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: NaCl 0.9%
Description: Patient who undergo surgery, debridement, decompression and posterior stabilization injection with Nacl 0.9% 2 ml
Study NCT02881190 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RC48-ADC
Study NCT03194074 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: In propofol/remifentanil group, propofol at a rate 75\~150 µg/kg/min and remifentanil at 0.1-0.3 µg/kg/min are maintained throughout surgery.
Study NCT03194074 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desflurane
Description: In desflurane/remifentanil group, desflurane at end tidal concentration at 0.7\~1.0 minimum alveolar concentration (MAC) and remifentanil 0.1-0.3 ug/kg/min are used.
Study NCT04114136 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nivolumab or Pembrolizumab (dependent upon approved indication)
Description: Anti-PD-1 mAb (monoclonal antibody)
Study NCT04114136 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab or Pembrolizumab (dependent upon approved indication)
Description: Anti-PD-1 mAb (monoclonal antibody)
Study NCT04114136 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Acts directly or indirectly on the liver to lower glucose production, and acts on the gut to increase glucose utilisation, increase GLP-1 and alter the microbiome.
Study NCT04114136 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosiglitazone
Description: A member of the thiazolidinedione class of antidiabetic agents, improves glycemic control by improving insulin sensitivity. Rosiglitazone is a highly selective and potent agonist for the peroxisome proliferator-activated receptor-gamma (PPARγ).
Study NCT01672294 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Preparation and life completion
Description: Caregiver subjects will discuss life review, issues of forgiveness and heritage and legacy.
Study NCT01672294 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Attention Control
Description: Caregiver subjects will listen to a non-guided relaxation CD with facilitator.
Study NCT03797989 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: P. vivax infected inoculum (parasitised red blood cells)
Description: In the first controlled human malaria infection (CHMI, Phase A), inoculation of parasitised red blood cells will be at three different doses (1 vial, 1:5 dilution, 1:20 dilution). The optimal inoculation dose will then be selected and administered to all participants in each of the second and third CHMI.
Study NCT04205656 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bone Marrow Concentrate (BMC)
Description: Participants will have a knee injected with BMC stem cells harvested from the iliac crest
Study NCT04205656 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control group (Placebo)
Description: Participants will undergo ACLR surgery with no injection into their knee.
Study NCT02308098 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide/Formoterol Easyhaler 320/9 ug/inhalation 4 inh
Study NCT02308098 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide/Formoterol Easyhaler 320/9 ug/inhalation 1 inh
Study NCT02308098 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Symbicort Turbuhaler 320/9 ug/inhalation 4 inh
Study NCT02308098 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Symbicort Turbuhaler 320/9 ug/inhalation 1inh
Study NCT02308098 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Symbicort Turbuhaler 320/9 ug/inhalation 4 inh
Study NCT02308098 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Budesonide/Formoterol Easyhaler 320/9 ug/inhalation 4 inh
Study NCT02308098 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Budesonide/Formoterol Easyhaler 320/9 ug/inhalation 1 inh
Study NCT02308098 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Symbicort Turbuhaler 320/9 ug/inhalation 1 inh
Study NCT00889837 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled Loxapine
Description: Staccato Loxapine, 10 mg x 2 doses, 10 hours apart
Study NCT00889837 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Inhaled Placebo
Description: Staccato Placebo, inhalations x 2 , 10 hours apart
Study NCT03840109 — intervention group
Intervention type: BEHAVIORAL
Intervention: Questionnaire 1a
Description: Participants will be randomly shown two versions of messages in which the last 20% of the message consists of negative statements of criticism and rate of the effectiveness of the message.
Study NCT03840109 — intervention group
Intervention type: BEHAVIORAL
Intervention: Questionnaire 1b
Description: Participants will be randomly shown two versions of messages in which the first 20% of the message consists of negative statements of criticism and rate of the effectiveness of the message.
Study NCT03840109 — intervention group
Intervention type: BEHAVIORAL
Intervention: Questionnaire 2a
Description: Participants will be randomly shown two versions of messages in which the last 40% of the message consists of negative statements of criticism and rate of the effectiveness of the message.
Study NCT03840109 — intervention group
Intervention type: BEHAVIORAL
Intervention: Questionnaire 2b
Description: Participants will be randomly shown two versions of messages in which the first 40% of the message consists of negative statements of criticism and rate of the effectiveness of the message.
Study NCT03840109 — intervention group
Intervention type: BEHAVIORAL
Intervention: Questionnaire 3a
Description: Participants will be randomly shown two versions of messages in which the last 60% of the message consists of negative statements of criticism and rate of the effectiveness of the message.
Study NCT03840109 — intervention group
Intervention type: BEHAVIORAL
Intervention: Questionnaire 3b
Description: Participants will be randomly shown two versions of messages in which the first 60% of the message consists of negative statements of criticism and rate of the effectiveness of the message.
Study NCT03840109 — intervention group
Intervention type: BEHAVIORAL
Intervention: Questionnaire 4a
Description: Participants will be randomly shown two versions of messages in which the last 80% of the message consists of negative statements of criticism and rate of the effectiveness of the message.
Study NCT03840109 — intervention group
Intervention type: BEHAVIORAL
Intervention: Questionnaire 4b
Description: Participants will be randomly shown two versions of messages in which the first 80% of the message consists of negative statements of criticism and rate of the effectiveness of the message.
Study NCT03109509 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fitbit + Pokemon Go
Description: Participants received a Fitbit Zip to wear daily for 8 weeks. Participants also received access to the Pokemon Go game.
Study NCT03109509 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Fitbit Only
Description: Participants received a Fitbit Zip to wear daily for 8 weeks.
Study NCT02080377 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glibenclamide
Study NCT02080377 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin
Study NCT04811898 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LNA-i-miR-221
Description: LNA-i-miR-221, IV daily infusion on days 1-4 followed by 24 days washout (1 cycle lasting 28 days)
Study NCT04134715 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06826647
Description: 100 mg tablet
Study NCT04134715 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Contraceptive (OC)
Description: OC in the form of 1 PORTIA (30 µg EE and 150 µg LN) or equivalent tablet
Study NCT04081389 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: Given PO
Study NCT04081389 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study NCT01589809 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nicotinamide
Description: dose-escalation, 2-8 grams, oral
Study NCT01765608 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zonisamide
Description: Zonisamide (Zonegran®) tablets will be administered according to a forced stepwise weekly titration scheme with weekly 100 mg escalations from 100 to 300 mg daily according to the manufacturer Eisai Inc.
Study NCT01765608 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Study NCT01765608 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: nCPAP
Study NCT04081389 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Given IV
Study NCT04081389 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: Given IV
Study NCT04081389 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV
Study NCT04081389 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Interferon Alfa-2b
Description: Given IV
Study NCT04081389 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rintatolimod
Description: Given IV
Study NCT02108626 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine
Description: E-Cigarette with nicotine cartridge
Study NCT02108626 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: E-Cigarette with 0mg nicotine cartridge
Study NCT03980132 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lugols Strong Iodine
Description: 5 L.I. drops / 8 hours for 10 days before surgery
Study NCT01121536 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Armodafinil
Description: Armodafinil tablets, taken orally, once daily in the morning
Study NCT03991598 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise program
Description: Exercise program in communities / Exercise program at home
Study NCT00241969 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral and Nutrition Treatment
Description: This intervention will combine individualized nutrition counseling that targets increasing energy and fat intake and parent training of effective behavioral child management skills. The treatment is delivered through 8 weekly sessions followed by 4 monthly sessions, each lasting around 60 minutes.
Study NCT00241969 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education and Attention Control
Description: This intervention will provide information about a number of aspects of their child's CF care and also provides anticipatory guidance for preschoolers.The treatment is delivered through 8 weekly sessions followed by 4 monthly sessions, each lasting around 60 minutes.
Study NCT03450148 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pavlok wristband with electric stimulus
Description: it is a device for various behavior modifications in the form of wristband which participants will wear on the wrist. Device has maximum voltage of 0-500 volts, delivers a electric stimulus for a maximum of 1 sec and average duration of 0.2 secs
Study NCT03450148 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Pavlok wristband without electric stimulus
Description: it is a device for various behavior modifications in the form of wristband which participants will wear on the wrist. Participants will not receive any electric stimulus since this feature will be turned off.
Study NCT01340040 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI-573
Description: MEDI-573 will be administrated once 7 days in Cohort 1 and 2, and once every 21 days in Cohort 3 as a IV infusion as part of a 21-day treatment cycle.
Study NCT01674517 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montelukast sodium chewable tablets 4mg and 5mg
Description: Montelukast sodium chewable tablets 4mg and 5mg
Study NCT01674517 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Montelukast sodium chewable tablets 4mg and 5mg
Description: Montelukast sodium chewable tablets 4mg and 5mg
Study NCT01940289 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Algometric meter readings for perception of pain
Study NCT02941419 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Platelet lysate
Description: Autologous intramuscular platelet lysate injection for patients with peripheral arterial disease
Study NCT03671239 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Placebo rectal insert
Description: Participants will be instructed to insert in the rectum a placebo insert prior to RAI. If a dose is missed, participants will be instructed to wait to take a dose at the next occurrence of RAI. Furthermore, if no RAI activity occurs at all in a given 7-day period, participants will be instructed to take a dose on the seventh day in the absence of RAI.
Study NCT03671239 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Placebo rectal suppository
Description: Participants will be instructed to insert in the rectum a placebo suppository prior to RAI. If a dose is missed, participants will be instructed to wait to take a dose at the next occurrence of RAI. Furthermore, if no RAI activity occurs at all in a given 7-day period, participants will be instructed to take a dose on the seventh day in the absence of RAI.
Study NCT03671239 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Placebo rectal douche
Description: Participants will be instructed to insert in the rectum a placebo douche (enema bottle with approximately 120 mL of clean tap water or bottled water) prior to RAI. If a dose is missed, participants will be instructed to wait to take a dose at the next occurrence of RAI, or if no other RAI activity occurs in that 7-day period, to take a dose in the absence of RAI. Furthermore, if no RAI activity occurs at all in a given 7-day period, participants will be instructed to take a dose on the seventh day in the absence of RAI.
Study NCT02992444 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard adhesive strip
Description: This is a standard adhesive strip (hydrocolloid)
Study NCT02992444 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental adhesive strip
Description: This is a strip of a newly developed adhesive.
Study NCT05090475 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Academic detailing intervention
Description: Academic detailing or educational outreach is a method based on scientific data with the help of educated A-team members in the form of direct (face-to-face) interactions, prescribing practices change and adherence improves according to the application of currently valid therapeutic guidelines
Study NCT03318783 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GSK2256294
Description: GSK2256294 will be administered in a single dose once daily enteral for a duration of 10 days.
Study NCT03318783 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered in a single dose once daily enteral for a duration of 10 days.
Study NCT01558778 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: management of therapy complications
Description: Undergo mechanical stimulation
Study NCT01558778 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: musculoskeletal complications management/prevention
Description: Undergo mechanical stimulation
Study NCT02605096 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MRI
Description: Magnetic Resonance Imaging Scan
Study NCT02605096 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: X-ray
Description: X-ray exam (conventional radiography)
Study NCT04609839 — intervention group
Intervention type: OTHER
Intervention: Follow-up of patients with COVID-19
Description: The presence of sequelae, number of re-hospitalizations, date of death and cost of health expenditure will be collected.~The Quality of life score (SF-36 questionnaire) and the Pittsburgh sleep quality index (PSQI questionnaire) will be completed by patients.
Study NCT04647318 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Compassion focused imagery, relaxation imagery and control task
Description: Participants will engage in three tasks (control task, relaxation imagery, and CFI) every three days on a total of 3-4 occasions. Audio-recordings of scripts will be used for both relaxation and compassion imagery. The 4-minute relaxation imagery will involve the following components (i) breathing deeply and bringing mindful awareness to the breath, (ii) relaxing the body, (iii) multisensory mental imagery of a beach or a forest, (iv) noticing feelings that arise. The 4-minute self-compassion imagery scripts will involve the following components: (i) informing participants that showing ourselves self-compassion is an effective emotional-regulation tool, (ii) breathing deeply and attending mindfully to the breath, (iii) imagining oneself embodying the four characteristics of compassion according to Gilbert5, (iv) imagine wishing oneself free of suffering using a warm voice tone and (v) noticing feelings that arise. The control task will involve reading a local city culture magazine.
Study NCT02419963 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: endoscopy for tissue biopsy
Description: endoscopy to obtain tissue biopsy for analysis of biomarker status
Study NCT02419963 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Blood Sample
Description: Blood draw to evaluate serotonin and Vit D level.
Study NCT02419963 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Stool Sample
Description: Stool sample to evaluate microbiome fingerprint.
Study NCT01717170 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Tocilizumab (4 mg/kg or 8 mg/kg)
Study NCT02390661 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Penrose drain placement
Description: A penrose drain will be placed in the lumpectomy cavity after removal of the irradiation catheter
Study NCT05810441 — intervention group
Intervention type: OTHER
Intervention: Evaluation of diagnostic accuracy of anti-ttg-m
Description: Mucosal anti-ttg evaluated in intestinal biopsy samples
Study NCT01732341 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: STENTYS self-apposing stent
Description: Intervention to treat STEMI with the STENTYS self-apposing stent
Study NCT01732341 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: VISION balloon-expandable stent
Description: STEMI treatment with a VISION balloon-expandable stent~--------------------------------------------------------------------------------
Study NCT04846855 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: local anaesthetic injection
Description: Realization by the anesthesiologist of the local anesthesia by single dose of ropivacaine 0.35% in perinervous under ultrasound with distraction by a tablette.
Study NCT02368899 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Computerized Alcohol Misuse Intervention
Description: Interventionaire© is a computerized alcohol misuse intervention that includes a normative feedback component unique in its micro-targeting of alcohol use feedback based on participant demographic characteristics (race/ethnicity, gender, and age), drawing population normative data from the National Surveys on Drug Use and Health. This represents a novel use of epidemiological data to inform clinical services.